Literature DB >> 33468244

Transplantation of retinal pigment epithelium and photoreceptors generated concomitantly via small molecule-mediated differentiation rescues visual function in rodent models of retinal degeneration.

Harshini Surendran1, Swapna Nandakumar1, Vijay Bhaskar Reddy K1, Jonathan Stoddard2, Varsha Mohan K3, Pramod K Upadhyay3, Trevor J McGill2, Rajarshi Pal4.   

Abstract

BACKGROUND: Age-related macular degeneration (AMD) is a result of degeneration/damage of the retinal pigment epithelium (RPE) while retinitis pigmentosa (RP), an inherited early-onset disease, results from premature loss of photoreceptors. A promising therapeutic approach for both is the replacement of lost/damaged cells with human induced pluripotent stem cell (hiPSC)-derived retinal cells.
METHODS: The aim of this study was to investigate the in vivo functionality of RPE and photoreceptor progenitor (PRP) cells derived from a clinical-grade hiPSC line through a unified protocol. De novo-generated RPE and PRP were characterized extensively to validate their identity, purity, and potency.
RESULTS: RPE expressed tight junction proteins, showed pigmentation and ciliation, and secreted polarization-related factors vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF). PRP expressed neural retina proteins and cone and rod markers, and responded to KCl-induced polarization. Transcriptomic analysis demonstrated an increase in the expression of mature retinal tissue-specific genes coupled with concomitant downregulation of genes from undesired lineages. RPE transplantation rescued visual function in RCS rats shown via optokinetic tracking and photoreceptor rescue. PRP transplantation improved light perception in NOD.SCID-rd1 mice, and positive electroretinography signals indicated functional photoreceptor activity in the host's outer nuclear layer. Graft survival and integration were confirmed using immunohistochemistry, and no animals showed teratoma formation or any kind of ectopic growth in the eye.
CONCLUSIONS: To our knowledge, this is the first demonstration of a unified, scalable, and GMP-adaptable protocol indicating strong animal efficacy and safety data with hiPSC-derived RPE and PRP cells. These findings provide robust proof-of-principle results for IND-enabling studies to test these potential regenerative cell therapies in patients.

Entities:  

Keywords:  Age-related macular degeneration; Induced pluripotent stem cells; Photoreceptor; Retinal pigment epithelium; Retinitis pigmentosa

Mesh:

Substances:

Year:  2021        PMID: 33468244      PMCID: PMC7814459          DOI: 10.1186/s13287-021-02134-x

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   6.832


  42 in total

1.  In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction.

Authors:  Fumitaka Osakada; Zi-Bing Jin; Yasuhiko Hirami; Hanako Ikeda; Teruko Danjyo; Kiichi Watanabe; Yoshiki Sasai; Masayo Takahashi
Journal:  J Cell Sci       Date:  2009-08-11       Impact factor: 5.285

2.  Human ESC-derived retinal epithelial cell sheets potentiate rescue of photoreceptor cell loss in rats with retinal degeneration.

Authors:  Karim Ben M'Barek; Walter Habeler; Alexandra Plancheron; Mohamed Jarraya; Florian Regent; Angélique Terray; Ying Yang; Laure Chatrousse; Sophie Domingues; Yolande Masson; José-Alain Sahel; Marc Peschanski; Olivier Goureau; Christelle Monville
Journal:  Sci Transl Med       Date:  2017-12-20       Impact factor: 17.956

3.  Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration.

Authors:  Bin Lu; Christopher Malcuit; Shaomei Wang; Sergej Girman; Peter Francis; Linda Lemieux; Robert Lanza; Raymond Lund
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

4.  Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs.

Authors:  Ruchi Sharma; Vladimir Khristov; Aaron Rising; Balendu Shekhar Jha; Roba Dejene; Nathan Hotaling; Yichao Li; Jonathan Stoddard; Casey Stankewicz; Qin Wan; Connie Zhang; Mercedes Maria Campos; Kiyoharu J Miyagishima; David McGaughey; Rafael Villasmil; Mary Mattapallil; Boris Stanzel; Haohua Qian; Wai Wong; Lucas Chase; Steve Charles; Trevor McGill; Sheldon Miller; Arvydas Maminishkis; Juan Amaral; Kapil Bharti
Journal:  Sci Transl Med       Date:  2019-01-16       Impact factor: 17.956

5.  Retinitis pigmentosa: genes and disease mechanisms.

Authors:  Stefano Ferrari; Enzo Di Iorio; Vanessa Barbaro; Diego Ponzin; Francesco S Sorrentino; Francesco Parmeggiani
Journal:  Curr Genomics       Date:  2011-06       Impact factor: 2.236

6.  Allogenic iPSC-derived RPE cell transplants induce immune response in pigs: a pilot study.

Authors:  Elliott H Sohn; Chunhua Jiao; Emily Kaalberg; Cathryn Cranston; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

7.  Foxg1 is required to limit the formation of ciliary margin tissue and Wnt/β-catenin signalling in the developing nasal retina of the mouse.

Authors:  Vassiliki Fotaki; Rowena Smith; Thomas Pratt; David J Price
Journal:  Dev Biol       Date:  2013-04-24       Impact factor: 3.582

8.  Transplantation of Photoreceptor Precursors Isolated via a Cell Surface Biomarker Panel From Embryonic Stem Cell-Derived Self-Forming Retina.

Authors:  Jorn Lakowski; Anai Gonzalez-Cordero; Emma L West; Ya-Ting Han; Emily Welby; Arifa Naeem; Samuel J I Blackford; James W B Bainbridge; Rachael A Pearson; Robin R Ali; Jane C Sowden
Journal:  Stem Cells       Date:  2015-05-27       Impact factor: 6.277

9.  Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications.

Authors:  Behnam Ahmadian Baghbaderani; Adhikarla Syama; Renuka Sivapatham; Ying Pei; Odity Mukherjee; Thomas Fellner; Xianmin Zeng; Mahendra S Rao
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

10.  Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation.

Authors:  Trevor J McGill; Osnat Bohana-Kashtan; Jonathan W Stoddard; Michael D Andrews; Neelay Pandit; Lior R Rosenberg-Belmaker; Ofer Wiser; Limor Matzrafi; Eyal Banin; Benjamin Reubinoff; Nir Netzer; Charles Irving
Journal:  Transl Vis Sci Technol       Date:  2017-06-14       Impact factor: 3.283

View more
  7 in total

Review 1.  Molecular Mechanisms of Retinal Pigment Epithelium Dysfunction in Age-Related Macular Degeneration.

Authors:  Jongmin Kim; Yeo Jin Lee; Jae Yon Won
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

2.  Administration of Melatonin in Diabetic Retinopathy Is Effective and Improves the Efficacy of Mesenchymal Stem Cell Treatment.

Authors:  Samraa H Abdel-Kawi; Khalid S Hashem
Journal:  Stem Cells Int       Date:  2022-04-11       Impact factor: 5.131

Review 3.  New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics.

Authors:  Juhee Ryu
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

Review 4.  Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy.

Authors:  Rajani Battu; Dhanashree Ratra; Lingam Gopal
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

5.  Global Transcriptional and Epigenetic Reconfiguration during Chemical Reprogramming of Human Retinal Pigment Epithelial Cells into Photoreceptor-like Cells.

Authors:  Xiaoqian Deng; Ryan Lee; Sin Yee Lim; Zheng Zhong; Jing Wang; Yizhi Liu; Guoping Fan
Journal:  Cells       Date:  2022-10-06       Impact factor: 7.666

6.  A defined subset of clonal retinal stem cell spheres is biased to RPE differentiation.

Authors:  Tahani W Baakdhah; Brenda Coles; Derek van der Kooy
Journal:  iScience       Date:  2021-05-21

Review 7.  Stem Cell Therapy for Retinal Degeneration: The Evidence to Date.

Authors:  Amit Sharma; Bithiah Grace Jaganathan
Journal:  Biologics       Date:  2021-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.